TuHURA Biosciences Inc
HURA2.450USD
-0.050-2.00%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
122.29MMarket Cap
LossP/E TTM
More Details of TuHURA Biosciences Inc Company
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).
TuHURA Biosciences Inc Info
Ticker SymbolHURA
Company nameTuHURA Biosciences Inc
IPO dateJul 12, 2016
CEODr. James Bianco, M.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address10500 University Center Dr.
CityTAMPA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33612
Phone18138756600
Websitehttps://tuhurabio.com/
Ticker SymbolHURA
IPO dateJul 12, 2016
CEODr. James Bianco, M.D.
Company Executives of TuHURA Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
1.88K
--
Mr. George Ng
Mr. George Ng
Independent Director
Independent Director
--
--
Dr. Craig Tendler, M.D.
Dr. Craig Tendler, M.D.
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Dr. James S. Manuso, Ph.D.
Dr. James S. Manuso, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. James Bianco, M.D.
Dr. James Bianco, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Dan Dearborn, CPA
Mr. Dan Dearborn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan List, M.D.
Dr. Alan List, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
1.88K
--
Mr. George Ng
Mr. George Ng
Independent Director
Independent Director
--
--
Dr. Craig Tendler, M.D.
Dr. Craig Tendler, M.D.
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Dr. James S. Manuso, Ph.D.
Dr. James S. Manuso, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. James Bianco, M.D.
Dr. James Bianco, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Sep 20
Updated: Sat, Sep 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Patel (Vijay)
15.65%
Patel (Samir Rashmikant)
5.41%
Bianco (James A)
4.55%
Nachtrab (Matthew)
4.52%
The Vanguard Group, Inc.
4.44%
Other
65.42%
Shareholders
Shareholders
Proportion
Patel (Vijay)
15.65%
Patel (Samir Rashmikant)
5.41%
Bianco (James A)
4.55%
Nachtrab (Matthew)
4.52%
The Vanguard Group, Inc.
4.44%
Other
65.42%
Shareholder Types
Shareholders
Proportion
Individual Investor
34.02%
Investment Advisor
9.68%
Investment Advisor/Hedge Fund
2.79%
Corporation
1.78%
Research Firm
0.15%
Pension Fund
0.13%
Bank and Trust
0.13%
Hedge Fund
0.04%
Other
51.29%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
99
6.53M
12.78%
+2.15M
2025Q2
61
22.69M
48.75%
+618.64K
2025Q1
62
22.01M
50.38%
+1.51M
2024Q4
59
20.49M
48.45%
+20.45M
2024Q3
46
25.82K
1.63%
-5.58K
2024Q2
47
25.48K
1.61%
+5.54K
2024Q1
51
16.48K
5.54%
+3.94K
2023Q4
52
9.23K
7.03%
+1.15K
2023Q3
58
5.06K
11.22%
-4.59K
2023Q2
63
4.35K
10.03%
-4.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Patel (Vijay)
8.00M
15.65%
--
--
Sep 11, 2025
Patel (Samir Rashmikant)
2.77M
5.41%
+452.84K
+19.57%
Sep 11, 2025
Bianco (James A)
2.32M
4.55%
--
--
Sep 11, 2025
Nachtrab (Matthew)
2.31M
4.52%
+2.31M
--
Sep 11, 2025
The Vanguard Group, Inc.
2.23M
4.37%
+358.71K
+19.13%
Jun 30, 2025
Theofilos (Charles Steve)
1.98M
3.87%
--
--
Jul 31, 2025
BlackRock Institutional Trust Company, N.A.
1.22M
2.39%
+874.93K
+251.87%
Jun 30, 2025
Geode Capital Management, L.L.C.
582.99K
1.14%
+307.26K
+111.43%
Jun 30, 2025
MainStreet Advisors
473.56K
0.93%
--
--
Jun 30, 2025
KP Biotech Group LLC
447.23K
0.88%
-1.68M
-78.96%
Jun 12, 2025
View more
Related ETFs
Updated: 19 hours ago
Updated: 19 hours ago
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
Date
Type
Ratio
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
